Skip to content
sellWeak cluster of 510b5-1 plan

Sarah Gheuens sold $98k of AGIO

Chief Medical Officer at AGIOS PHARMACEUTICALS, INC.. 2,909 shares at an average of $33.54, traded Jun 24, 2025, filed Jun 26, 2025.

Warning score
5
Value
$98k
2,909 shares
Holdings after
56,988
-5% from before
From 52-week low
+36%
low $24.53, close $33.42
From 52-week high
-46%
high $61.64, as of Jun 24, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $98k at market
    +10
  • Share of holdings sold
    Sold 4.9% of holdings
    0
  • Cluster
    5 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AGIOOct 9, 2026 · close 31.81
Since filing Jun 26, 2025: -5.5%SPY +29.0% · excess -34.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001439222-25-000069, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 24, 2025MOption exercise
Common stock10b5-1
+6,000$0.00$059,897Jun 26, 2025
Jun 24, 2025SOpen-market sale
Common stock10b5-1
-2,909$33.54$98k56,988Jun 26, 2025
Jun 24, 2025MOption exercise
Performance share unitsderivative10b5-1
-6,000$0.00$06,000Jun 26, 2025

Related signals

Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Brian Goff
Chief Executive Officer
$627k
18,700 shares
-16%
5Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Tsveta Milanova
Chief Commercial Officer
$93k
2,770 shares
-10%
9Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Cecilia Jones
Chief Financial Officer
$60k
1,780 shares
-6%
5Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
James William Burns
Chief Legal Officer
$94k
2,799 shares
-9%
0Weak
AGIOsell10b5-1
AGIOS PHARMACEUTICALS, INC.
Jacqualyn A Fouse
director
$194k
7,497 shares
-5%
12Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Theodore James Washburn Jr.
Principal Accounting Officer
$59k
1,655 shares
-26%
6Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Sarah Gheuens
Chief Medical Officer
$142k
4,005 shares
-8%
27Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Brian Goff
Chief Executive Officer
$460k
12,947 shares
-15%
2Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Tsveta Milanova
Chief Commercial Officer
$60k
1,681 shares
-7%
16Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Cecilia Jones
Chief Financial Officer
$81k
2,275 shares
-10%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Sarah Gheuens sold $98k of AGIO | InsiderTell